We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Mitochondrial Clearance Failure Provides Diagnostic Marker for Parkinson's Disease

By LabMedica International staff writers
Posted on 07 Oct 2019
Failure of mitochondria to remove the Miro1 protein following depolarization provides a biomarker that can be used for diagnosis of Parkinson's disease.

Miro1 (Mitochondrial Rho GTPase 1) is an enzyme that facilitates mitochondrial transport by attaching the mitochondria to the motor/adaptor complex. More...
Through its key role in mitochondrial transport, Miro1is involved in mitochondrial homeostasis and apoptosis, as well as Parkinson’s disease (PD) and cancer. Miro1 is localized on the mitochondrial surface and mediates mitochondrial motility. Normally, it is removed from depolarized mitochondria to facilitate their clearance via mitophagy.

Investigators at Stanford University (Palo Alto, CA, USA) had previous identified the inability to remove Miro from damaged mitochondria as a mitochondrial-clearance defect in the cells of Parkinson's disease patients' cells. To explore the possibility of using this defect as a diagnostic marker, the investigators analyzed skin fibroblast samples from 83 Parkinson's patients, five asymptomatic close relatives considered to be at heightened risk, 22 patients diagnosed with other movement disorders, and 52 healthy control subjects.

Results revealed that the Miro-removal defect was present in 78 of the 83 Parkinson's fibroblasts (94%) and in all five of the "high-risk" samples, but not in fibroblasts from the control group or from patients with other movement-disorders.

"We have identified a molecular marker that could allow doctors to diagnose Parkinson's accurately, early, and in a clinically practical way," said senior author Dr. Xinnan Wang, associate professor of neurosurgery at Stanford University. "This marker could be used to assess drug candidates' capacity to counter the defect and stall the disease's progression."

The study was published in the September 26, 2019, online edition of the journal Cell Metabolism.

Related Links:
Stanford University


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining Management Software
DakoLink
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.